The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study. by Leila Dorling, Siddhartha Kar, Kyriaki Michailidou, Louise Hiller, Anne-Laure Vallier, Susan Ingle, Richard Hardy, Sarah J Bowden, Janet A Dunn, Chris Twelves, Christopher J Poole, Carlos Caldas, Helena M Earl, Paul D P Pharoah, Jean E Abraham

Get full text

Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD d... by Roberto D’Amico, Valentina Guarneri, PierFranco Conte, Heikki Joensuu, Xavier Pivot, Vassilis Georgoulias, Louise Hiller, Janet A Dunn, Mubarak Patel, Teppo Huttunen, Helena M Earl, Dora Hatzidaki, Jean E Abraham, David Miles, David A Cameron, Andrew M Wardley

Get full text

Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer by Angela Santonja, Wendy N Cooper, Matthew D Eldridge, Paul A W Edwards, James A Morris, Abigail R Edwards, Hui Zhao, Katrin Heider, Dominique‐Laurent Couturier, Aadhitthya Vijayaraghavan, Paulius Mennea, Emma‐Jane Ditter, Christopher G Smith, Chris Boursnell, Raquel Manzano García, Oscar M Rueda, Emma Beddowes, Heather Biggs, Stephen‐John Sammut, Nitzan Rosenfeld, Carlos Caldas, Jean E Abraham, Davina Gale

Get full text

A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer by Rita A. Mukhtar, Soumya Gottipati, Christina Yau, Sara López-Tarruella, Helena Earl, Larry Hayward, Louise Hiller, Marie Osdoit, Marieke van der Noordaa, Diane de Croze, Anne-Sophie Hamy, Marick Laé, Fabien Reyal, Gabe S. Sonke, Tessa G. Steenbruggen, Maartje van Seijen, Jelle Wesseling, Miguel Martín, Maria del Monte-Millán, Judy C. Boughey, Matthew P. Goetz, Tanya Hoskin, Vicente Valero, Stephen B. Edge, Jean E. Abraham, John M. S. Bartlett, Carlos Caldas, Janet Dunn, Elena Provenzano, Stephen-John Sammut, Jeremy S. Thomas, Ashley Graham, Peter Hall, Lorna Mackintosh, Fang Fan, Andrew K. Godwin, Kelsey Schwensen, Priyanka Sharma, Angela M. DeMichele, Kimberly Cole, Lajos Pusztai, Mi-Ok Kim, Laura J van ’t Veer, David Cameron, Laura J. Esserman, W. Fraser Symmans

Get full text

Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial by Jean E. Abraham, Lenka Oplustil O’Connor, Louise Grybowicz, Karen Pinilla Alba, Alimu Dayimu, Nikolaos Demiris, Caron Harvey, Lynsey M. Drewett, Rebecca Lucey, Alexander Fulton, Anne N. Roberts, Joanna R. Worley, Ms Anita Chhabra, Wendi Qian, Jessica Brown, Richard Hardy, Anne-Laure Vallier, Steve Chan, Maria Esther Una Cidon, Elizabeth Sherwin, Amitabha Chakrabarti, Claire Sadler, Jen Barnes, Mojca Persic, Sarah Smith, Sanjay Raj, Annabel Borley, Jeremy P. Braybrooke, Emma Staples, Lucy C. Scott, Cheryl A. Palmer, Margaret Moody, Mark J. Churn, Domenic Pilger, Guido Zagnoli-Vieira, Paul W. G. Wijnhoven, Mukesh B. Mukesh, Rebecca R. Roylance, Philip C. Schouten, Nicola C. Levitt, Karen McAdam, Anne C. Armstrong, Ellen R. Copson, Emma McMurtry, Susan Galbraith, Marc Tischkowitz, Elena Provenzano, Mark J. O’Connor, Helena M. Earl, PARTNER Trial Group

Get full text